Company Overview and News

to your dashboard

Headline News

Road To Financial Independence: My December 88-Stock Portfolio Review

2018-01-15 seekingalpha
The year closed with a bang, with stock markets rallying strong, dividend income rising and more buying. (367-3)

Galapagos Reports Topline Data From Osteoarthritis Study

2018-01-08 zacks
Galapagos NV (GLPG - Free Report) announced positive top-line data from phase Ib study evaluating its osteoarthritis (“OA”) candidate, GLPG1972. The candidate reduced the level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in its highest dosage. (74-0)

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

2017-12-20 seekingalpha
Despite recent doom and gloom talk that came as a result of the pullback in fall, it has still been a decent year. (482-1)

The Only Reason Why Gilead Might Not Buy Galapagos Straight Away

2017-12-19 seekingalpha
The lockup and standstill arrangement under the companies' January 2016 agreement expires at the end of this month. (15-0)

Your Daily Pharma Scoop: Gilead Remains Long-Term Story, Argenx Rallies, Bluebird Data

2017-12-12 seekingalpha
Today we will discuss an article on Gilead Sciences (GILD) by William Meyers, titled, “Gilead Sciences: Going Down When It Should Go Up.” (70-2)

Gilead Doubles Down On CAR-T: Updates To Thesis

2017-12-10 seekingalpha
Shares initially rose after calling the stock a core buy in biotech, but the stock has pulled back as a result of volatility in the sector and HCV concerns. (26-0)

Galapagos: Buy The Dip

2017-12-10 seekingalpha
The company has several irons in the fire considering their CF candidates, filgotinib and promising early-stage IPF asset.

Gilead's Wild Rollercoaster - Where Is It Heading?

2017-12-06 seekingalpha
Gilead's HCV business is declining but its HIV segment and future impact from the Kite acquisition are largely ignored. (14-0)

Your Daily Pharma Scoop: Teva Valuation, DelMar Lead Candidate, Galapagos Commences Trial

2017-11-22 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (291-7)

Galapagos' CF Candidate Shows Potential in Phase II Study

2017-11-20 zacks
Galapagos NV (GLPG - Free Report) announced positive top-line data from a phase II study – ALBATROSS – evaluating its cystic fibrosis transmembrane conductance (“CFTR”) corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function. (77-1)

Galapagos: Strong Buy From Europe

2017-11-08 seekingalpha
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene’s dramatic failure in Crohn’s Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody’s CD pipeline. The Celgene (NASDAQ:CELG) drug was thought to have $1bn potential, and Gilead (NASDAQ:GILD) has a $2bn separate deal with this $4.5bn market cap company. So we are talking good numbers here. (71-0)

Your Daily Pharma Scoop: Gilead's Unappreciated Opportunity, Merck's Keytruda Stumble, Epizyme's Positive Results

2017-10-30 seekingalpha
Epizyme’s tazemetostat showed positive results in pediatric patients with relapsed or refractory INI1-negative molecularly defined solid tumors. (509-1)

Gilead: The Bad News, Then The Good News, Then Some Guesses

2017-10-27 seekingalpha
GILD sank a few more points on weak HCV sales guidance for Q4 and likely beyond. (82-0)

Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View

2017-10-26 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. (111-0)

This Pharma Stock Is Up 111% and Investors Are Wondering What's Next - Bloomberg

2017-10-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (96-0)